EP0472662A1 - Polypeptides anti-congelateurs - Google Patents

Polypeptides anti-congelateurs

Info

Publication number
EP0472662A1
EP0472662A1 EP90909325A EP90909325A EP0472662A1 EP 0472662 A1 EP0472662 A1 EP 0472662A1 EP 90909325 A EP90909325 A EP 90909325A EP 90909325 A EP90909325 A EP 90909325A EP 0472662 A1 EP0472662 A1 EP 0472662A1
Authority
EP
European Patent Office
Prior art keywords
antifreeze
protein
polypeptide
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90909325A
Other languages
German (de)
English (en)
Other versions
EP0472662A4 (en
Inventor
Gareth J. Warren
Gunhild M. Mueller
Robert L. Mckown
Pamela Dunsmuir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DNA Plant Technology Corp
Original Assignee
DNA Plant Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/350,481 external-priority patent/US5118792A/en
Application filed by DNA Plant Technology Corp filed Critical DNA Plant Technology Corp
Publication of EP0472662A1 publication Critical patent/EP0472662A1/fr
Publication of EP0472662A4 publication Critical patent/EP0472662A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8273—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for drought, cold, salt resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Definitions

  • This invention relates generally to reagents useful in improving the freezing tolerance of otherwise sensitive organic materials. These reagents increase the frozen storage life of, e.g., foodstuffs and other biological materials and maximize retention of various properties during storage or upon exposure to freezing.
  • frozen foods have become a mainstay of the human diet.
  • frozen vegetables in particular, and frozen desserts, such as ice cream have been the subject of extensive research by food processors.
  • recrystallization can have a substantial negative impact on the taste and texture of frozen foods.
  • frost-free freezers has exacerbated this situation, which has been more traditionally associated with temperature fluctuations during transportation. After a relatively short period of time at other than sub-zero temperatures or even at sustained freezing temperatures, many frozen foods become less desirable, or worse, totally unsuitable, for human consumption.
  • freezing can cause extensive damage.
  • the freezing process itself kills most eukaryotic cells, and cells subjected to even one freezing and thawing cycle exhibit greatly reduced viability.
  • loss of viability in yeast cells from freezing and thawing reduces the fermentative and subsequent bread leavening activity of these cells.
  • Impaired function of living cells is also prevalent in tissue cryopreservation, with concomitant drawbacks for organ transplants.
  • frost or other freezing damage to plants presents a serious problem in agriculture.
  • drugs can become ineffective, or even dangerous, if not maintained under required strict temperature conditions.
  • the present invention provides new and effective means to avoid many of the destructive or deteriorating effects of freezing and is widely applicable in its various embodiments to maximize retention of important properties of organic materials through the freezing and thawing processes. Its various embodiments address, inter alia, food storage, cryoprotection of medicinally used biologies and protection of agriculturally valuable plant products.
  • the present invention provides novel methods and compositions for improving frozen storage life and other characteristics of organics and biological materials, such as frozen foods and biologies, through use of antifreeze polypeptides, preferably in substantially pure form. They further may be used in protecting agricultural products from damage from freezing climatic conditions.
  • antifreeze polypeptides ae provided, the most preferred will typically comprise at least about 2 segments with sequences homologous to a consensus sequence, LTAAN AAAAAA, as well as additional amino acid segments or moieties, dependent upon desired additional characteristics.
  • the antifreeze polypeptides assist in suppressing ice crystal growth in foodstuffs and biologies, without harming desirable aspects of the food or decreasing the viability of the biologic.
  • the invention relates to methods for producing novel compositions comprising antifreeze polypeptides in combination with the organic materials.
  • the invention relates to production of the antifreeze polypeptides, preferably by recombinant or chemically synthetic means. Specifically, cloning and expression of nucleic acid sequences encoding the polypeptides, their expression, purification and various methods of use are also provided.
  • FIG. 1 shows the amino acid abbreviations.
  • Fig. 2 is a listing of the core repetitive sequences of the synthetic antifreeze polypeptides.
  • Fig. 3 is a listing of especially preferred antifreeze polypeptide sequences.
  • Fig. 4 is a listing of specific preferred antifreeze synthetic gene sequences and their corresponding amino acid seguences.
  • Fig. 5 is a list of fusion polypeptides and their uses.
  • Fig. 6 is a list of the nucleotide sequences used to prepare the Saf proteins and the saf genes.
  • Fig. 7 is the splat assay photographs for various uses of antifreeze polypeptides.
  • Fig. 8 describes the plasmid constructions for the plant transformations.
  • Fig. 9 is an autoradiograph of a gel showing expression in the plant transformation experiment. Results of the RNase protection experiment. Lane 1: probe alone Lane 2: Yeast tRNA Lane 3: RNA from transformant not expressing antifreeze gene Lane 4: RNA from 3499-APNB transformant #1 Lane 5: RNA from 2964-APNB transformant #2 Lane 6: RNA from 2964-APNB transformant #3 Lane 7: RNA from 2964-APNB transformant #4 Lane 8: RNA from 2964-APNB transformant #5 Lane 9: RNA from 2964-APNB transformant #6 Lane 10: pBR322 Hpall molecular weight markers
  • Fig. 10 shows the development of recrystallization in extracts of yeast expressing a Protein-A-Saf5 fusion of the present invention.
  • Fig. 11 shows the development of recrystallization in extracts of yeast expressing a Protein-A-Saf4 fusion of the present invention.
  • substantially pure polypeptides typically free from, e.g., contaminating naturally-occurring compounds (such as fish or insect extract) , that exhibit ice crystal growth suppression activity are provided for use in improving or maintaining various characteristics of frozen or chilled foods and biologies.
  • the antifreeze polypeptides can be in their native configuration or designated in accordance with the formula (NH 2 ) XI - X2 - X3 (COOH) , where XI comprises a site specifically cleavable moiety, X2 is a polypeptide comprising at least two segments with a sequence homologous to a sequence LTAAN AAAAAA, and X3, if present, comprises a terminal amino acid sequence.
  • XI can consist essentially of: a) a heterologous fusion partner polypeptide and, if present, a spacer segment; b) a substantially stoichiometrically cleavable amino acid or polypeptide and, if present, one or more spacer segments; c) a non-amino acid moiety; or d) an oligopeptide segment other than an antifreeze segment typically between about 2 and 20 amino acids.
  • XI will comprise amino acid sequence which does not contain aspartate and X2 will comprise at least about 3 tandem segments, each of about 11 amino acids in length and comprising: a) all alanines except between one and four substituted amino acids selected from the group of D, E, K,
  • antifreeze polypeptides will have an XI region that is stoichiometrically cleavable by reagent, such as cyanogen bromide or an enzyme, preferably an enzyme that does not cleave the X2 region.
  • Particularly preferred amino terminal segments comprise methionine, MAA, or IEGR.
  • the X2 segments will be between about two and ten segments homologous to the consensus sequence and preferably three to five adjacent segments.
  • a preferred amino acid segment within X2 will have the sequence DTASD AAAAAA, and more preferably as the amino proximal sequence.
  • X3, if present, may consist essentially of a fusion partner amino acid sequence with optional accompanying spacer segments or a terminal amino acid sequence.
  • X3 will preferably comprise any of the following amino acid sequences:- ATAA; ATAR; ATAK; ATAAAAAR; or ATAAAAAK.
  • the polypeptides are preferably produced by expressing recombinant nucleic acid sequences encoding the desired sequence.
  • the antifreeze polypeptide wil be less than about 7,000 daltons, but when fusion proteins are produced the molecular weight may exceed about 10,000 daltons, or more, depending upon the ultimate use.
  • the recombinant nucleic acids typically comprise at least about 20 nucleotides which are homologous to nucleic acid sequence encoding an amino acid sequence of, e.g.. Fig. 3, or which will hybridize under stringent conditions, of temperature or salt, to nucleic acid sequences encoding such amino acid sequences.
  • recombinant nucleic acid sequences will have synthetic segments having selected codon usage, comprising predetermined restriction or cleavage sites and further comprising sequences coding for newly introduced protease cleavage sites of the ultimate protein.
  • the recombinant sequences typically will be linked to a promoter sequence not normally associated with a naturally occurring polypeptide yet operable in a transformed host cell.
  • polypeptides of the present invention are capable of minimizing potential freezing damage to biologic or foodstuff compositions when added in a sufficient amount to suppress ice crystal growth.
  • Various other additives may also be incorporated in the compositions, particularly generally known stabilizers for the added polypeptides. See e.g., Zapsalis and Beck (1985) Food Chemistry and Nutritiona Biochemistry. John Wiley and Sons, New York and Belitz and Grosch (1987) Food Chemistry. Springer-Verlag, New York, bot of which are incorporated herein by reference.
  • the subject polypeptides may be added directly to the biologic or foodstuff in accordance with procedures well known to those skilled in the biologies or food processing arts.
  • plants or cells may be transformed wit recombinant nucleic acid sequences encoding the polypeptides which will then be produced as desired, such as during the growth of a plant, particularly dicotyledonous.
  • the principle of ice crystal growth suppression is a non-colligative property of the antifreeze polypeptides involving interference with the addition of water to the ice lattice (adsorption inhibition) of an ice crystal. This mechanism is also seemingly different from the process which occurs upon initial nucleation or formation of the crystal.
  • the rate of crystal growth determines the size of crystals while the nucleation rate determines the number of crystals.
  • novel proteins of the presen invention seemingly function to inhibit the addition of new water molecules to an ice crystal by binding to the growing crystal face and blocking sites for further crystal growth.
  • the subject polypeptide sequences are capabl of suppressing growth and recrystallization of ice crystals in various organic materials.
  • These antifreeze polypeptides have a number of distinctive properties and uses, as described more specifically below.
  • antifreeze polypeptide refers to a polypeptide exhibiting the activity of inhibiting the growth of ice crystals in a sample. This activity is also referred to as ice crystal growth suppression.
  • the growth-inhibited ice crystal will typically be at least about 10% to 20% smaller than non-inhibited ice crystals at a set point in time after onset of freezing, preferably at least about 40 to 50% smaller, more preferably at least about 65 to 75% smaller and most preferably about 95 to 99% smaller.
  • a freezing protective amount of an antifreeze polypeptide will be a guantity sufficient to provide a desired level of inhibition of crystal growth.
  • the preferred method is to use a modified "spla assay" described below.
  • the assay consists of applying a solution of the protein to a cooled metal block and comparing the size of ice crystals formed after an appropriate time interval with a sample lacking the antifreeze polypeptide.
  • antifreeze peptides see. DeVries (1983), Ann. Rev. Physiol. 45:245-60 and Feeney (1988) Comments Aorric. and Food Chemistry. 1:47-181, both of which are incorporated herein b reference.
  • polypeptide sequences contain amin acid segments which exhibit strong homologies to particular consensus sequences.
  • the single letter abbreviations are those commonly used by biochemists and listed in Fig. 1. Se Stryer, Biochemistry, 3d Ed., W.H. Freeman & Company, New
  • ITAan AaaAAa where the capital letters are amino acids identically conserved in seven given segments and the lowercase letters are the most common amino acids in those positions.
  • the blank is between the fifth and sixth amino acids merely for ease in counting how many amino acids are in the segment.
  • Other useful segment sequences are given in Fig. 4.
  • Homologous segments are those segments having sequences with greater than about 50% matching with the amino acids of the consensus sequence, typically greater than about 70%, and preferably greater than about 90%. All seven of the given segments in Fig. 2, typel through type7, exhibit homology ranging from over 70% to total identity with the consensus sequence. Other segments which exhibit similar properties are listed in Fig. 4. Amino acid segments which exhibit homology to these segments of Fig.
  • antifreeze segments may be modified but should retain homology to the sequences in Figs. 2 or 4. They are generally modified by substituting, preferably conservative amino acids, into various positions, preferably into the positions not identically conserved in the listed segments of Fig. 2.
  • conservative substitutions are meant substitutions within the groups as follows: gly, ala; val, ile, leu; asp, glu; asn, gin; ser, thr; lys, arg; and phe, tyr.
  • antifreeze polypeptides will typically contain two or more antifreeze segments, each preferably about eleven amino acids in length.
  • the antifreeze polypeptide component portion will vary from at least about 2,200 daltons to about 10,000 daltons, typically between about 3,000 and 7,000 daltons, and preferably about 3,500 to 6,000 daltons.
  • antifreeze segments are typically found i tandem, but may still retain activity with intervening amino acid segments between them. Although not intended as a limitation, there are indications that intervening segments most likely should preserve a conformational constraint within the antifreeze segments, and the likely limitations o intervening spacer segments require a multiple of about thre and two thirds amino acid residues (meaning, e.g., three, four, seven, eight, eleven, fourteen, fifteen, etc).
  • the antifreeze polypeptide may retain its activity to suppress ice crystal growth even having an occasional insertion or deletion of an amino acid in a segment, though there may be limitations on the possible modifications consistent with retention of activity. At least two of these homologous antifreeze segments will usually be contained within the polypeptides of the present invention.
  • An antifreeze polypeptide may have as many as ten or more segments, but usually less than seven and in the preferred embodiment, three through five.
  • the number of homologous segments may determine the effectiveness of a single molecule in suppressing crystal growth, or may determine the molar number of molecules necessary to have an effect.
  • a correlation has been observed between recrystallization inhibition activity and number of segments when increased from three to four to five, evidencing a direct relationship between activity and number of repeats.
  • the amino terminus of the polypeptide will typically comprise a site specifically cleavable moiety comprising one or more amino acids, preferably amino acid sequences selected from the group of: a) M (methionine) ; b) MAA; c) a spacer segment containing the sequence IEGR d) amino acid sequences susceptible to site specific cleavage; and e) an amino acid sequence which serves as a fusion peptide, thereby possibly conferring multifunctional character to the fusion polypeptide.
  • These amino terminal sequences will typically confer resistance to proteolytic degradation of the antifreeze segments, but may also, or alternatively, confer a second biological or other activity.
  • the moiety may also be a non-peptide extension such as a sugar, such as glucose, galactose and fucose, or be composed of a polymer of such sugars.
  • Methionine by itself, is easily removable by treatment with cyanogen bromide, and thus falls into both categories (a) and (d) .
  • MAA, or methionine-alanine-alanine is a short, simple hydrophobic amino acid sequence.
  • IEGR serves as a spacer and is the recognition and cleavage site for factor X_ of the blood clotting cascade.
  • the moiety susceptible to site specific cleavage typically can be site specifically cut in a simple process, while not cleaving internally in the antifreeze segments so as to preserve the ice crystal growth suppression activity. Cleavage need not be stoichiometric, but will usually be nearly quantitative. While it need not be a single step reaction, preferably the process will not require a complex series of reagents. Simplicity can be conferred by a steady state type reaction system, or possibly by passing through a column wherein proteolytic enzymes will function on the sample as it passes through.
  • the means for site specific cleavage will generall include enzymatic cleavage.
  • proteases For polypeptides, this will typically be performed by site-specific proteases, which exhibit specificity in recognition and cutting of particular amino acid sequences.
  • exemplary proteases include trypsin, chymotrypsin, pepsin, papain, subtilisin, elastase or V8 protease.
  • An alternative method is to treat with a chemical agent which causes breakage at a particular site.
  • a classic example is the use of cyanogen bromide to cleave methionine, a reaction exhibiting high selectivity.
  • the carboxy- terminus of the antifreeze polypeptid will normally be: i) ATAA; ii) ATAR; iii) ATAK; iv) ATAAAAAR; or V) ATAAAAAK. Although these are the preferred terminal sequences, additional sequences may be substituted. These are generall somewhat hydrophobic, but others may be utilized. The most common fusions will be segments which will confer onto the resultant protein particular advantageous properties, as indicated for resistance to destruction or degradation. Se Fig. 5. Also envisioned in the invention are polypeptides having modifications to the polypeptide chain, including acetylations, methylations, derivatizations and glycosylations where the polypeptides have antifreeze properties.
  • a heterologous fusion protein may comprise additional polypeptide or other segments attached to the amino- or carboxy-terminus (or both) of the antifreeze polypeptide. Surprisingly, the antifreeze activity of the antifreeze segments is retained, even when the segments are embedded in a fusion protein.
  • the fusion protein of the present invention will normally comprise one or more domains from a heterologous protein, such as a protein which is normally targeted to a particular cellular compartment, into which the homologous antifreeze polypeptides or antifreeze segments are to be introduced.
  • This site-specific targeting may provide improved production, such as through easier purification or secretion from a host (which, if desired, can involve cleavage of the targeting component as part of the secretion process) . It may also be utilized to target these polypeptides to particular cell types. Targeting may be important for efficacy of the product.
  • Another desirable property of the fusion partner polypeptide may be a particular affinity or reactivity. This affinity may provide improved detectability or production, such as through easier purification (e.g., by affinity chromatography through, e.g., Protein A (Sigma)) or measurement (e.g., by Western blots or enzyme assays) .
  • the fusion segment will confer onto the antifreeze segment the property of being directed or transported to a predetermined cellular compartment.
  • Such segments are specifically intended to exclude homologous antifreeze protein signal peptides, although leader sequences are particularly useful for extracellular secretion.
  • Various examples include yeast alpha-factor which will be secreted, ribulose bisphosphate carboxylase which will be transported into the chloroplasts, phytohemagglutinin which is transported into vacuoles, cytochrome c which is transported into mitochondria, alpha- amylase which is secreted from monocotyledonous plants and pathogenesis-related protein PR1B which is secreted from dicotyledonous plants.
  • viral proteins which are targeted to the nucleus and will confer greater resistance to significant freezing induced degradation of th nucleic acids or other components of the nucleus are embrace herein.
  • the antifreeze segments are coupled to a targeting component which has selectivity for attachment or integration into particular cell types.
  • the targeting of the antifreeze activity to specific cell types greatly increases the selectivity of protection. For example, after targeting, and upon freezing of a cell culture, those cells which have become cryoprotected might selectively survivethe freezing process.
  • peptide fusions include, but are not limited to. Protein A, / 3-galactosidase, .-lactamase, chloramphenicol acetyltransferase, alcohol dehydrogenase, alpha amylase, luciferase, phytohemagglutinin RuBPCase small subunit, phaseolin or yeast alpha mating factor.
  • Fig. 5 provides a representative list, not comprehensive, of suitable fusion proteins and their properties. The seguences of fusion proteins and various antifreeze polypeptides are available from, e.g., GenBank (National Institutes of Health) , the relevant portions of which are incorporated herein by reference.
  • a recombinant nucleic acid sequence results from the joining of two segments of nucleic acid which would not otherwise be joined in nature.
  • the separate nucleic acid segments originate from different species, but may come from two different individuals, or even different cells of the same individual.
  • the term "recombinant nucleic acid sequence" also includes a chemically synthesized nuclei acid segment having a selected sequence joined to another segment from any other source.
  • the synthetic segment is used instead o a natural source, because a particular nucleic acid sequence is desired which may be different from known natural seguences.
  • a synthetic sequence is used to change a codon or to change codon usage, or to introduce or remove restriction enzyme recognition sites.
  • Particular codon selection may be different for the purpose of higher translation efficiency in the target expression system making use of the differential codon usage of a given host, to avoid particular codons or to change the amino acid sequence of a resulting polypeptide.
  • Introduction or removal of particular restriction enzyme recognition or cutting sites may be important to assist in the process of generating a particular sequence having desirable characteristics, including the introduction or removal of new or different sequence segments. It may also be utilized to introduce a new sequence, for example, new protease cleavage sites.
  • Synthetic segments are particularly useful in view of the general repetitive nature of the antifreeze segments.
  • By appropriate design of the nucleic acid segments making up the repeats it is possible to generate various nucleic acid segments encoding individual segments but with specific restriction enzyme cut sites.
  • By selection of the appropriate enzymes it is possible to simply introduce particular coding sequences into previously made antifreeze polypeptides.
  • the possibility of mixing and matching combinations of the segments may be readily achieved, making the testing of the various combinations much easier and faster.
  • nucleic acid encodes a single antifreeze segment with the restrictio sites located at the ends, it is possible to have the restriction enzyme cut sites internal to the repeat segment with the introduced segment spanning the boundary of a particular repeat segment.
  • an alternative embodiment of the present invention includes recombinant nucleic acid sequences coding for engineered polypeptides containing the antifreeze segments as defined above.
  • These recombinant nucleic acid sequences include segments which encode antifreeze polypeptides, e.g., of Figs. 2, 3 or 4, and homologous sequences.
  • Substantial homology in the nucleic acid context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned with appropriate nucleotide insertions or deletions, in at least about 60% to 70% of the residues, usually at least about 80%, and preferably at least 90% of the nucleotides.
  • substantial homology exists when the segments will hybridize under selective hybridization conditions, to strand, or its complement, typically using a seguence derive from Figs. 2, 3 or 4.
  • Selectivity of hybridization exists when hybridization occurs which is more selective than total lack of specificity.
  • selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14/25 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90%. See. Kanehisa, M. (1984) , Nucleic Acids Res. 12:203-213, which is incorporated herein by reference.
  • Stringent hybridization conditions will typically include salt concentrations of less than about 1 M, more usually less than about 500 mM and preferably less than about 200 mM.
  • Temperature conditions will typically be greater than 20°C, more usually greater than about 30°C and preferably in excess of about 37°C. As other factors may significantly affect the stringency of hybridization, including, among others, base composition and size of the complementary strands, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one.
  • sequences also include nucleic acids encoding antifreeze polypeptides containing either fusion protein segments or segments which are engineered with additional desired sequences.
  • This will include synthetic nucleic acid sequences which have incorporated unnatural sequences, typically for the purposes of substituting different codons, (particularly to match codon usage to the preferred codon usage of the expressing host cell) modifying the amino acid sequence of the resultant polypeptide, removing or adding restriction enzyme recognition or cutting sites or modifying upstream or downstream sequences in regulation of the expression of the polypeptide.
  • the preferred embodiments of the antifreeze segments contain, and are flanked by, recognition sites for restriction enzymes with hexa- and octa-nucleotide specificity.
  • they are flanked by the following sites: EcoRI, SstI, Smal, Kpnl, Mrol, BamHI, SphI, Hindlll (not all sites flank any one gene) .
  • they contain the following sites: Ncol, Nhel, Bgll, SacII, NotI, PvuII, and Hpal. These sites are useful in the construction and manipulation of the antifreeze-codin sequences.
  • the codon usage of the preferred embodiments differ from that of the currently-known antifreeze genes from fish or insects.
  • Optimal codon usage will facilitate translation in each species targeted for expression of antifreeze genes.
  • preferred codon usages in prokaryotes, in yeast, and in higher plants differ from the codon usage found in winter flounder antifreeze genes (Maruyama et al.. Nucleic Acids Research. 1 Suppl. 151-189) .
  • the codons GCA, GCG, an GCT together account for more than 65% of the alanine codons in known genes of E. coli. S.. cereyisiae, and Z.. mays wherea they account for less than 35% of the alanine codons in know antifreeze genes of winter flounder (P. americanus) .
  • codons ACA, ACG, and ACT together account for most of the threonine codons in known genes of E. coli (51%) S.. cerevisiae (70%) and Z . mays (66%) , whereas they account for less than 25% of the threonine codons in known antifreez genes of P. americanus.
  • nucleic acid segment encoding the antifreeze polypeptide into a different surrounding sequence environment is contemplated, for example, to place the nucleic acid segment under the operational control of an upstream promoter or enhancer element.
  • a sequence When a sequence is under operational control of the promoter, it is operably linked to the promoter. Operational linkage between the promoter and a coding sequence will normally exist when located within about a thousand nucleotides upstream of the ribosome binding site (if present) , preferably within about five hundred nucleotides and most preferably within about three hundred nucleotides and at the distance wherein the promoter will have its most desirable effect.
  • the promoter will typically be chosen to be one which will result in strong transcription of the segment, oftentimes constitutively.
  • a typical constitutive strong promoter is the 35S promoter of cauliflower mosaic virus.
  • an inducible promoter will be desired.
  • a typical inducible promoter is the lac promoter.
  • a developmentally regulated promoter will be preferred, such as the RUBPCase small subunit promoter of plants.
  • a promoter which is functional in the ultimate target host will be desired, but occasionally a different promoter might be selected.
  • a large assortment of vectors are available and may be appropriate depending upon the use intended.
  • expression vectors typically between about 1,000 and 5,000 nucleotides or more
  • strong promoters ensuring that the nucleic acid sequence will be expressed producing large quantities of polypeptide.
  • a vector containing the tryptophan promoter may be a preferred vector having a high expression level.
  • Other similar promoters will be the ⁇ - galactosidase promoter or the promoter in phage ⁇ . Properties useful or important in selection of the promoter or the vector are addressed in Maniatis et al. Molecular
  • Plasmids or phage will typically be the preferred vectors for bacteria.
  • T7 polymerase system One particular system which will allow high message level expression with particularly low levels of contaminating message is the T7 polymerase system.
  • E. coli is co-transformed with a coding segment operably linked to a T7 promoter and with an inducible and rifampicin insensitive T7 polymerase. Upon induction of the polymerase in the presence of rifampicin, highly specific transcription of the intended sequence will result.
  • promoters such as the SV40 T antigen, thymidine ki ⁇ ase or /3-globin might be preferred.
  • Particular yeast promoters which might be selected include the GAL1,10 .Mol. & Cell Biol.. (1984) 4:1440-1448), ADH 2 (J. Biol. Chem.. (1983) 258:2674-2682) and PH05 fEMBO J.. (1982) 6:675-680) promoters.
  • preferred promoters include the 35S promoter from cauliflower mosaic virus, the promoter for the small subunit of ribulose bisphosphate carboxylase (RuBPCase) and the nopaline synthase promoter from Agrobacterium tumefaciens.
  • RuBPCase ribulose bisphosphate carboxylase
  • nopaline synthase promoter from Agrobacterium tumefaciens.
  • the insect baculovirus system can be very efficient. See Luckow & Summers (1988) Bio/Technology. 6:47-55. These vector systems typically allow for simple and efficient protein purification.
  • the primary ultimate use of this invention is the use of the antifreeze polypeptides to bind to ice crystal faces blocking the growth of the crystal.
  • the inhibition of ice crystal growth requires the presence of the polypeptide, so production of the polypeptide is very important.
  • Synthesis may be pursued in two forms, either biological or synthetic.
  • the biological method is by expression of polypeptide coding sequence or gene; the synthetic method is by chemical synthesis of a polypeptide.
  • a preferred synthetic method utilizes solid phase peptide synthesis, such as that developed by Merrifield (J. Am. Chem. Soc.. (1963) 85:2149-2156). This method will be particularly useful in testing particular compositions or formulations for antifreeze activity. For large scale production, the biological expression would typically be preferred.
  • the encoding nucleic acid or gene can be a natural gene with recombinant modifications or a totally synthetic sequence that will be expressed in an appropriate expression system.
  • restriction enzyme cutting sites may be introduced which will provide convenient segments which may be easily linked together or inserted to generate tandem repeats, as will be obvious to one of ordinary skill in the art.
  • Purification of the antifreeze polypeptides will be by methods known to a person of ordinary skill in the art of protein purification. Standard purification techniques may be from either cell lysates or culture medium if the proteins are secreted. Typical methods are column chromatography, ammonium sulfate salt precipitations, antibody affinity column chromatography and others. With naturally occurring polypeptides (e.g., produced in fish), a preferred method of purification is as described by DeVries et al. (1977)
  • the antifreeze polypeptides will be purified to substantial homogeneity, usually at least about 70% to 80% pure, preferably about 90-95% pure, most preferably 99% or more pure.
  • the polypeptides will be substantially free of contaminating, naturally associated (e.g., fish blood or insect cell) compounds.
  • the polypeptides or genes encoding the polypeptides may be used in ways to suppress ice crystal growth.
  • the polypeptide may be introduced in the protein form, or it may be introduced as a gene which is expressed endogenously at a level which should be attainable by expressing an antifreeze protein in the plant cell under the control of a suitable strong promoter to produce the polypeptide(s) .
  • suitable concentrations of antifreeze polypeptides will vary depending on the use, but will typically be in the range of from about one part per billion to about one part per thousand (e.g., from about 1 ⁇ g/1 to 1 gm/1 for fluids, preferably between about 0.01 to about 0.1 mg/ml) .
  • the polypeptides will be introduced to foodstuffs.
  • This has a number of different aspects.
  • One is the introduction into plant foodstuffs, either into the entire plant and thus conferring some degree of general resistance to damage from subfreezing climatic conditions, or into a plant part such a the fruit or vegetable portion to minimize damage specifically to those particular plant organs upon freezing.
  • Exemplary plant parts are stems, roots, leaves, flowers, petioles, pericarp, seeds, vegetative tissue, tubers and so forth.
  • the texture, taste, and useful storage life of frozen vegetables will be improved, for example, celery, potatoes, asparagus, peas, carrots, beans, broccoli, sweet corn and spinach.
  • the texture, taste and useful storage life of fruits will be enhanced, including strawberries, blueberries, raspberries, citrus fruits, bananas, grapes, kiwis, peaches, pineapples, plums, cherries tomatoes and mangoes.
  • nucleic acid either constitutively or inducibly, before food processing has begun, or after harvesting and processing has begun, may lead to sufficientl high levels of the polypeptide to effectively protect the foodstuff, such as up to about 0.1% of total plant protein b mass.
  • Expression can also be on a tissue specific basis. For example, linkage to ripening genes in fruits may result in expression even after harvesting from the producing plant
  • the polypeptides may also be added into foods whic are expected to be frozen.
  • frozen foods are intended t be consumed in the cold state, for example, ice cream, froze yogurt, ice milk, sherbet, popsicles, frozen whipped cream, frozen cream pies, frozen puddings and the like.
  • texture and flavor are adversely affected by the formation of large ice crystals throughout a freeze-thaw cycle that occurs in most home frost-free freezers or upon sustained storage in the frozen state.
  • This ice crystal growth process may be prevented entirely, or at least minimized by the addition of antifreeze polypeptides.
  • the antifreeze agent may be either incorporated throughout the foodstuff, or may, alternatively, be applied to the surface where condensation and crystal formation is expected to occu most readily.
  • Another important use is to transform dough yeast with nucleic acids encoding these proteins. Upon incorporation and expression of this gene into the yeast, and use of these yeast in frozen dough, the dough will naturally leaven upon thawing because the yeast viability will remain high upon thawing. Because less damage accumulates from storage in the presence of these antifreeze polypeptides and thawed samples preserve high viability, either longer storage times result or much smaller aliquots are needed for storage.
  • antifreeze proteins to protect plants from climatic freezing conditions.
  • the antifreeze protein or polypeptide may be either internally incorporated into the cytoplasm by expression of an introduced gene, or the polypeptides may be externally applied to the plants. External application may be achieved either by direct application of the polypeptides to the plant, or by the external deposit onto the plant of an organism which secretes the polypeptide.
  • Another embodiment is the introduction of an antifreeze polypeptide into liquid surrounding an organ, tissue or other biological sample. One particular use would be during transportation to a hospital for a transplantation operation or for storage purposes.
  • the antifreeze polypeptide should allow short- or long-term storage at a subfreezing temperature, thereby minimizing inherent metabolism or degradation, but with substantially diminished cellular damage from ice crystal growth.
  • Other medically important temperature sensitive biological samples are blood and blood products, therapeutic agents, protein drugs, bioassay reagents and vaccines.
  • an antifreeze polypeptide into cells or their extracts destined for frozen storage.
  • bacterial cells, yeast cells, plant cells and, most particularly, animal cells containing the antifreeze proteins have increased cell or tissue viability with minimal or no loss of inherent characteristics due to the freeze-thaw process.
  • Subcellular samples or cellular extracts may have similar sensitivities to freezing, especially on prolonged storage. Typical examples will be in vitro protein translation systems, enzym preparations, and particularly samples which contain sensitive membrane components, such as chloroplast or mitochondrial membrane preparations.
  • samples containing organelles may display increased resistance to freezing damage upon addition of these antifreeze polypeptides.
  • Soft animal tissues will exhibit less damage upon freezing in the presence of the subject polypeptides, and addition of the polypeptides will be useful in situation when cellular integrity upon freezing and subsequent thawing is important or desired, such as for tissue culture deposits
  • samples destined for frozen storage such as for cell or tissue depositories, might routinely have the polypeptide added to them.
  • cell types often stored are geneti variants of bacteria, fungi (including yeast) , and, particularly, higher eucaryote cells (such as hybridoma strains and tissue culture cell lines) .
  • Antifreeze fusion polypeptides of the present invention may be targeted to a particular cellular compartment or to extracellular space, to a particular cell or to particular cell types, all in accordance with well known procedures.
  • the antifreeze segments may be targeted to a particular cellular organelle. Not only will the peptide be directed to the organelle, but the antifreeze function may remain functional even when surrounded by other polypeptide segments.
  • the resistance to cellular damage upon freezing can be conferred to those cell types. This technique will also find use in organs.
  • compositions an uses based on the mixture of antifreeze polypeptides with stabilizers well known to those skilled in the art and other additives. These compounds may be present to inhibit decay, inhibit oxidation, prevent discoloration, inhibit microbial growth, stabilize emulsions and so forth.
  • nucleic acid constructs capable of introduction to and/or expression in the ultimate target expressing cell.
  • nucleic acid constructs will be suitable for replication in a unicellular or multicellular host, such as yeast or bacteria, but may also be intended for introduction and integration within the genome of cultured mammalian or other eukaryotic cell lines, in particular, plants.
  • Nucleic acid constructs prepared for introduction into bacteria or yeast will include a replication system recognized by the host, the nucleic acid fragment encoding the desired antifreeze polypeptide product, transcriptional and translational initiation regulatory seguences joined to the 5'-end of the antifreeze polypeptide encoding nucleic acid sequence, and transcriptional and translational termination regulatory sequences joined to the 3 --end of the sequence.
  • the transcriptional regulatory sequences will include a heterologous promoter which is recognized by the host.
  • available expression vectors which include the replication system and transcriptional and translational regulatory sequences together with an insertion site for the antifreeze polypeptide encoding sequence may be employed.
  • the gene will include any nucleic acid segment which contains a coding seguence for antifreeze polypeptide. Normally, the gene will include the coding sequence plus the upstream and downstream associated sequences, particularly any enhancer, promoter, ribosome binding site or transcription initiation markers. Downstream segments may also be important for message polyadenylation and processing and thus are also contemplated in the usual instance.
  • Constructs may additionally contain DNA encoding stabilizing peptide partners (e.g., DNA encoding chitinase for plant transformation) .
  • stabilizing peptide partners e.g., DNA encoding chitinase for plant transformation
  • the introduction of genes into cells or groups of cells for expression is another method for generally introducing the polypeptides into the sample of interest.
  • the end product of the transformation is also included a ⁇ th product of this invention, and the term "transformed cell” will include the actual cell transformed, and all progeny of that cell.
  • the final organism will contain cells, each of which will contain the gene. Standar transformation procedures exist for bacteria (Maniatis) , fungi (Sherman et al. (1986) in Laboratory Course Manual for Methods in Yeast Genetics. CSH), plants (van den Elzen et al (1985) Plant Mol. Biol.. 5:149-154) and animals (Hanahan, (1988) Ann. Rev. Genetics. 22:479-519).
  • the present invention also provides means for generating or isolating new polypeptides which will exhibit the ice crystal growth suppression activity. Discovering such polypeptides typically requires an accurate and, preferably, quick means for assaying the activity.
  • the method of choice is a "splat assay” modified from Knight et al. (1988) Crvobiology. 25:55-60, which is incorporated herein by reference. Recrystallization involves the growth of some crystals at the expense of others. Typically, growth is in the form of long thin spicules, (see DeVries (1983) "Antifreeze peptides and Glycopeptides in Cold-Water Fish” in Ann. Rev. Phvsiol.. 45:245-260, Fig.
  • the splat assay is comprised of dropping a small droplet of a solution of the polypeptide in an appropriate buffer onto a cooled plate.
  • the droplet "splats" onto the plate surface, freezes rapidly forming many small crystals and the recrystallization process is monitored visually after an appropriate time interval. Samples containing the antifreeze polypeptide exhibit a much decreased crystal size.
  • Synthetic homologous polypeptides such as those of the formula detailed above, may be readily assayed to determine what particular characteristics or sequences will be most effective. Alternatively, since the segments themselves are encoded in easily manipulated synthetic nucleic acid segments, insertions, deletions or substitutions into existing sequences are readily prepared, expressed and assayed.
  • antibodies against epitopes contained in the antifreeze segments may be raised to search for similar polypeptide sequences in other naturally occurring proteins.
  • insects or other organisms which are naturally exposed to subfreezing temperatures may be scrutinized for content of proteins possessing antifreeze properties.
  • the genes or nucleic acids encoding known segments can be used to select homologous nucleic acid segments, a somewhat preferred method because expression is unnecessary.
  • An antibody screen will be dependent on polypeptide expression, which may be developmentally or conditionally dependent.
  • Another method for selecting new polypeptides is to mutagenize known segments and assay the resultant product. While the splat assay- is also useful here, a simpler freeze- thaw cycle of expressing cells selects for those cells least sensitive to the freezing process; generally due to the expression of an effective antifreeze polypeptide.
  • EXAMPLE 1 Inhibition of recrystallization by a Betalactamase-Saf3-Betalactamase fusion protein.
  • DS oligo 1 was cloned between the Xmal and PstI sites of vector pUC118 to yield plasmid PLVC74.
  • Two DNA sequences each of 49 bases were synthesize chemically and annealed together to produce the double- stranded oligonucleotide with staggered ends shown as DS oligo 2 (see Fig. 6) .
  • DS oligo 2 was cloned between the Kpn and PstI sites of vector pUC118 to yield plasmid pLVC73.
  • Plasmid pLVC73 was treated with restriction enzyme SacII to release the double-stranded oligonucleotide with staggered ends shown as DS oligo 3 (see Fig. 6) .
  • DS oligo 3 was cloned into the SacII site of plasmid pLVC74 and the progeny were screened by sequencing to yield plasmid pLVC82, in which DS oligo 3 was shown to be inserted in the sense direction.
  • the SacII fragment in pLVC82 was reduplicated in direct orientation as described in this paragraph.
  • the principle of reduplicating restriction fragments is describe in Green et al. (1988) Mol. Gen. Genet.. 215:165-172.
  • the DNA of plasmid pLVC82 was extracted from the Rec+ E. coli K1 strain SK1592 (Warren & Green, (1985) J. Bacteriol.. 161:1103-1111), subjected to agarose gel electrophoresis, an the band corresponding to plasmid dimers was excised and its DNA recovered; this dimeric pLVC82 was amplified by transformation into the recA- E. coli K12 strain JC10291 (Willis et al.
  • Dimeric pLVC82 was digested partially by SacII and subjected to agarose gel electrophoresis; bands corresponding to approximately half the plasmid dimer were excised and their DNA recovered; the fragments of recovered DNA were recircularized by ligase treatment and transformed into strain JC10291.
  • the progeny of the SacII fragment-reduplication were screened by restriction analysis to find plasmid pLVC83, in which two copies of DS oligo 3 are present in tandem.
  • the antifreeze-encoding seguences in pLVC83 are known as gene saf3.
  • Plasmid pLVC83 was treated with restriction enzyme PstI to release an approx. 0.1 kbp DNA fragment containing saf3 sequences. This-short fragment was cloned into the PstI site of plasmid pBR322 (Balbas et al. (1986) Gene. 50:3-40) and the progeny were screened by restriction analysis to fin plasmid pLVC84, in which the 0.1 kbp fragment was shown to b inserted into pBR322 in the indicated direction. This inserts saf3 into an internal position in the bla (Betalactamase-encoding) gene of pBR322 and maintains the reading frame from the upstream portion of bla through saf3 and into the downstream portion of bla.
  • PstI restriction enzyme
  • Betalactamase-Saf3-Betalactamase fusion protein The effect of the Betalactamase-Saf3-Betalactamase fusion protein on the recrystallization of ice.
  • Plasmids pLVC84 (carrying the gene fusion) and pBR322 (to provide nonfused Betalactamase for a negative control) were transformed into E_. coli K12 strain JC10291.
  • the resultant bacterial strains were grown at 37"C in Luria broth (LB) to an optical density at 600 nm (O.D. 600 ) of approx. 1.0, harvested by centrifugation for 15 min. at 7000 rpm in an SS34 Sorvall rotor, and lysed by sonication in 10 mM EDTA/30 mM Tris-HCl pH 8.0.
  • EXAMPLE 2 Inhibition of recrystallization by a Protei A-Saf5 fusion protein and purification of said fusion protein.
  • Plasmid pLVC83 was treated with restriction enzyme EcoRI and Hindlll to release an approximately 0.1 kbp DNA fragment containing saf3. This fragment was cloned between the EcoRI and Hindlll sites of pUCH9 to yield plasmid pGMMl An internal SacII fragment of pGMMl was reduplicated as described in example 1. The products of this manipulation were screened by restriction analysis to find plasmid pLVC85, in which three copies of DS oligo 3 are present in tandem. The synthetic sequences in pLVC85 are known as gene saf4. A internal SacII fragment of pLVC85 was reduplicated as described in example 1.
  • pLVC86 The products of this manipulation were screened by restriction analysis to find plasmid pLVC86, in which four copies of DS oligo 3 are present in tandem.
  • the antifreeze-encoding sequences in pLVC86 are known as gen saf5.
  • Plasmids pLVC86 (containing saf5) and pRIT5 (containing the spa gene) (Nilsson et al. (1985) EMBO J..
  • Protein A-encoding gene and maintains the reading frame from the spa gene through saf5.
  • Plasmids pRLM105 (carrying the gene fusion) and pRIT5 (to provide nonfused Protein A for a negative control) were transformed into E. coli K12 strain SK1592. Crude extracts from the resultant strains were obtained as in example 1 and tested for recrystallization as in example 3. Ice crystals grew to an average diameter more than five-fold greater in the negative controls compared to the samples containing the fusion protein. Thus it was shown that the extract containing the Protein A-Saf5 fusion protein inhibited recrystallization, whereas the negative control did not.
  • Example 3 provides data for this fusion protein in pure form. This demonstrated that a peptide antifreeze attached by its amino-terminus to a foreign heterologous polypeptide can nevertheless function to inhibit recrystallization.
  • E. coli K12 strain SK1592 carrying plasmid pRLM105 was cultured at 37°C in 100 ml Luria broth (LB) containing 50 ⁇ gm/ml ampicillin until it reached an O.D. 600 of approx. 1.0. Cells were pelleted by 5 min. centrifugation at 3000 rpm in an SS34 rotor, and resuspended in 10 ml 30 mM Tris pH 8.1.
  • a column containing 1.5 ml IgG-Sepharose was washed by passage of 20 ml TST (150 mM NaCl, 0.05% Tween 20, 50 mM Tris-HCl pH 7.6). It was then prepared for use by successively passing 4 ml each of (i) 0.5 M Acetic Acid pH 3.4, (ii) TST, and (iii) 0.5 M Acetic Acid pH 3.4. TST was passed through again until the effluent buffer reached neutral pH. The periplasmic fraction was applied to the column and 15 ml TST and 3 ml 5 mM CH 3 C0 2 NH 4 were subsequently passed through.
  • the solution of purified fusion protein was stored at 4°C. This preparation of fusion protein was substantially pure as shown by polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) with subsequent visualization of protein by staining with Coomassie Brilliant Blue.
  • EXAMPLE 3 Inhibition of recrystallization by purified Protein A-Saf5 fusion protein in water, in popsicle mixture, and in an A&W frozen root beer float mixture.
  • the splat assay consists of: 10 ⁇ l of the purified Protein A-Saf5 fusion protein (made in example 2D) was added to 90 ⁇ l of water and was maintained on ice until used. As a control, 10 ⁇ l of a Protein A solution (0.5 mg/ml, in 20 mM Tris-HCl, pH 8.0) was added to 90 ⁇ l of water and also maintained on ice until use. A 10 ⁇ l droplet of the aqueous sample containing the fusion protein or a 10 ⁇ l droplet containing Protein A as the control were released from a height of 3.0 m and allowed to impact upon a polished aluminum plate that was resting upon a block of dry ice (about -75°C).
  • the droplet comes in contact with the surface of the cold metal, it instantly freezes and forms a "splat" approximately 10 mm in diameter and 50 ⁇ m thick with a composition of very small ice crystals.
  • the splat was then transferred with a cold carbon steel surgical blade (B-P #10) to a glass cryostage mounted on a dissecting microscope.
  • the procedure was to thaw a piece of the confectionery at room temperature, withdraw a small volume, add the SAF fusion protein (or buffer for the control) , splat 10 ⁇ l samples and photograph recrystallization over time. The additions accounted for 5% of the total volume and the final concentration of the SAF fusion protein mixture was 0.1 mg/ml. The first photographs were taken within 5 minutes after splatting and the remaining pictures show recrystallization at 15 min. , 30 min. and one hour. All samples were photographed at the same magnification (2OX) .
  • the root beer shell contains water, sugar, corn syrup, guar gum, caramel color, artificial and natural flavors and sodiu benzoate.
  • the product was manufactured by Merritt Foods (plant #29-409) , 2840 Guinotte, Kansas City, MO.
  • 10 ⁇ l of buffer (20 mM Tris-HCl, pH 8.0) was added to the thawed sample in place of 10 ⁇ l of the Protein A-Saf5 fusion protein in the same buffer.
  • the procedure was to thaw a piece of the confectionery at room temperature, withdraw a small volume, add the SAF fusion protein (or buffer for the control) , spla 10 ⁇ l samples and photograph recrystallizatio over time. Th additions accounted for 5% of the total volume and the final concentration of the SAF fusion protein mixture was 0.1 mg/ml. The first photographs were taken within 5 minutes after splatting and the remaining pictures show recrystallization at 15 min.”, 30 min. and one hour. All samples were photographed at the same magnification (2OX) .
  • Plasmid pGMMl was treated with restriction enzymes Aatll and Xmal and the 0.47 kbp fragment of released DNA was separated and purified. In a separate reaction, plasmid pGMMl was also treated separately with restriction enzymes Aatll and Nhel and the 2.7 kbp fragment of released DNA was separated and purified.
  • the spa gene-containing plasmid pRLMlOl was used as a vector for saf6.
  • pRLMlOl contains the spa gene derived from pRIT5.
  • the construction of pRLMlOl is described in this paragraph.
  • Plasmid pGMMl was treated with restriction enzymes Xmal and Pvul and the 1.75 kbp fragment of released DNA was separated and purified.
  • Plasmid pRIT5 was also treated with Xmal and Pvul and the 2.3 kbp fragment was purified. The purified 1.75 and 2.3 kbp fragments were ligated together to yield plasmid pGMM2.
  • Plasmid pGMM2 was digested by PstI and the 4.2 kbp fragment of released DNA was purified and treated with T4 DNA ligase to yield plasmid pRLMlOl.
  • Plasmids pRLMlOl and pGJ151 were each treated with restriction enzymes Ncol and Pvul and fragments of approx. size 2.3 kbp and 1.8 kbp were isolated from the respective digests. The isolated fragments were ligated together to yield plasmid pLVC94. This places saf6 downstream from the spa gene and maintains the reading frame from the spa gene through saf6.
  • Plasmid pLVC94 was transformed into E. coli K12 strain JC10291 carrying plasmid pLVC94, and the derivative strain carrying pLVC94 was cultured in 10 ml of LB at 37 ⁇ C until an O.D. 600 of 1.30 was reached. Cells were harvested b centrifugation at 6000xg for 5 min. and cell extracts were prepared by sonication in 0.5 ml of 10 mM EDTA, 30 mM Tris- HCl pH 8.0 at 4°C. The effect of the Protein A-Saf6 fusion protein present in the cell extracts on recrystallization in water was measured as described for the Betalactamase-Saf3- Betalactamase fusion protein in example 1.
  • Recrystallizatio was less than in the negative control: crystal size in the control became at least three-fold greater than in the Protein A-Saf6 sample. This demonstrated that Saf6 attached by its amino-terminus to a foreign fusion partner polypeptid can function to inhibit recrystallization.
  • EXAMPLE 5 Inhibition of recrystallization by a Protei A-Saf8 fusion protein.
  • Plasmid pGJ151 was treated with restriction enzymes PstI and Aatll and the approx. 0.9 kbp fragment of released DNA was separated and purified.
  • Plasmi pGMMl was treated with restriction enzymes Aatll and Hindlll and the 2.4 kbp fragment of released DNA was separated and purified. These 0.9 kbp and 2.4 kbp fragments were ligated together with DS oligo 5 to yield plasmid pGMM3. This manipulation has the effect of substituting the sequences of DS oligo 5 into the saf6 gene present in pGJ151.
  • the antifreeze-coding sequences in pGMM3 are known as gene saf8.
  • Plasmids pRLMlOl and pGMM3 were each treated with restriction enzymes Ncol and Pvul and fragments of approx. size 2.3 kbp and 1.8 kbp were isolated from the respective digests. The isolated fragments were ligated together to yield plasmid pLVC95. This places saf8 downstream from the spa gene and maintains the reading frame from the spa gene through saf8.
  • Plasmid pLVC95 was transferred into E. coli K12 strain JC10291 and the derivative strain carrying plasmid pLVC95 was cultured in LB at 37°C until reaching an O.D. 600 of 1.3. Cells were harvested by centrifugation at 6000xg for 5 min. and cell extracts were prepared by sonication in 0.5 ml of 10 mM EDTA, 30 mM Tris-HCl pH 8.0 at 4°C. The effect of the Protein A-Saf8 fusion protein present in the cell extracts on recrystallization in water was measured as was done for Betalactamase-Saf3-Betalactamase fusion protein in example 1. The result was that recrystallization was at least six-fold less than in the negative control. This demonstrated that Saf8 attached by its amino-terminus to a foreign polypeptide can function to inhibit recrystallization.
  • EXAMPLE 6 Purification of two Protein A-SaflO fusion proteins, inhibition of ice recrystallization by said purified fusion proteins in water, cleavage of one purified fusion protein by CNBr, and activity of naked Saf10 released by said CNBr cleavage.
  • Plasmid pGMM3 was treated with restriction enzymes EcoRI and NotI such that NotI gave incomplete digestion; DNA fragments of approx. size 81 bp were separated and purified. In a separate reaction, plasmi pGMM3 was also treated with restriction enzymes EcoRI and SacII and the approx. 3.2 kbp fragment of released DNA was separated and purified.
  • the spa gene-containing vector plasmid pGMM8 was constructed as described in this paragraph. Plasmid pUC118 was cut with PvuII and the 2.9 kbp fragment was ligated to a Bglll linker to yield plasmid pGJ153. Plasmid pUC118 was separately cut with EcoRI and Hindlll, and the 3.2 kbp fragment of released DNA was ligated together with DS oligo7 to yield plasmid pGJ154. Plasmid pGJ153 was treated with enzymes Bglll and Aatll and a fragment of 2.1 kbp was isolated.
  • Plasmid pGJ154 was treated with enzymes EcoRI and Aatll and a fragment of 0.95 kbp was isolated.
  • Plasmid pRIT2T Nilsson et al. (1985) EMBO J. 4:1075-1080) was treate with enzymes Bglll and EcoRI and a fragment of 0.9 kbp was isolated. These 2.1, 0.95, and 0.9 kbp fragments were ligated together to yield plasmid pGMM8.
  • Plasmid pGMM8 was treated with Ncol and BamHI and fragment of approx. 3.8 kbp was purified.
  • Plasmid pGMM5 was treated with Ncol and BamHI and a fragment of approx. 123 bp was purified.
  • the isolated 3.8 kbp and 123 bp fragments were ligated together to yield plasmid pGMM9, thus placing saf10 downstream from the spa gene, maintaining the reading frame from the spa gene through saf10, and placing a methionine codon at the spa-saflO junction.
  • Plasmid pGMM5 was treated with EcoRI and Nhel, and a fragment of approx. 3.2 kbp was purified. Two DNA sequences each of 34 bases were synthesized chemically and annealed together to produce the double-stranded oligonucleotide with staggered ends shown as DS oligo 8 (Fig. 6).
  • Plasmid pGMM7 was treated with EcoRI and BamHI and the released DNA fragment of approx. 0.15 kbp was purified; plasmid pGMM8 was treated with EcoRI and BamHI and the released DNA fragment of approx. 3.8 kbp was purified. The 0.15 and 3.8 kbp fragments were ligated together to yield plasmid pGMMlO.
  • Plasmid pGMMlO contains a spa-saflO gene fusion equivalent to that in pGMM9 except that the peptide linkage-encoding region supplied by DS oligo 8 is present as the junction between the spa and saf10 moieties.
  • Pellets derived from 100 ml cell cultures were resuspended in 6 ml of 100 mM Tris-HCl pH 8.0 containing 500 mM sucrose, 60 ⁇ l 40 mM leupeptin and 400 ⁇ l of 100 mM PMSF.
  • 120 ⁇ l lysozyme of 10 mg/ml were added, mixed briefly and then 6 ml of cold distilled water were added. After incubation at 4 C for 25 min., 25 ⁇ l of DNAse I at 10 mg/ml were added and the cells subjected to eight freeze-thaw cycles in liquid nitrogen and a 37°C waterbath.
  • the cell lysate was centrifuged for ten minutes at 20,000xg and the pellet was shown to be free of fusion protein by SDS-PAGE.
  • the supernatant containing the fusion proteins consists mostly o cytoplasmic proteins.
  • the fusion proteins were purified fro the extracts as described in example 2 and resuspended in 100 mM NaCl, 50 mM Tris-HCl pH 8.0 to final concentrations of 14 and 8 mg/ml respectively.
  • the solutions of the purified fusion proteins were stored at -20°C. An aliquot was subjected to polyacrylamide gel electrophoresis in the presence of SDS, and the gel was subsequently stained by Coomassie Brilliant Blue. The presence of a single intensely-stained band demonstrated that these preparations of fusion protein were substantially pure.
  • the largest an predominant among these new proteins was one whose size indicated cleavage of the fusion protein at approximately th junction of its Protein A and SaflO components. Band densities indicated that approximately 80% release of naked antifreeze had occurred, and that cleavage at other sites wa less than 50%. On this basis the naked antifreeze was expected to constitute more than 75% of the peptides smaller than 10 kDa but not visible after SDS-PAGE.
  • the protein mixture resulting from CNBr treatment was tested in the recrystallization-inhibition assay described in example 3(A) and was found to retain undiminished ability to retard recrystallization (compared to the untreated fusion protein) . The mixture was passed through a molecular filter with a cutoff of 10 kDa.
  • This 10 kDa. filtrate was expected to contain the "naked" or “free” antifreeze polypeptide (i.e., a polypeptide containing only the indicated polypeptide segments of the SAF) which the CNBr treatment was expected to have generated, but not the residual intact fusion protein or any of the smaller proteins visualized by SDS-PAGE.
  • the 10 kDa. filtrate was concentrated by passing it through a molecular filter with a cutoff of 3 kDa. and recovering the retentate. The resulting concentrate of the 10 kDa. filtrate was tested for recrystallization inhibiting activity as before.
  • EXAMPLE 7 Reconstruction experiments with purified Protein A-Saf5 fusion protein and extracts from plant tissue
  • the powder was then transferred to a capped polycarbonate tube and mixed by vortexing for 20 seconds with 2 ml of extraction buffer (50 mM NaHP0 4 pH 7.0, 10 mM DTT, 0.1% TRITO X-100, 1 mM Na 2 EDTA) .
  • the tube was then spun at 2700 rpm in Beckman TJ-6 centrifuge to pellet debris. 1 ml of the supernatant from this spin was spun for 5 minutes in an Eppendorf centrifuge. The clear supernatant was taken and the protein concentration determined using the protein assay kit from Bio-Rad.
  • the Protein A-Saf5 fusion protein was added to the plant extract and the resulting mixture was assayed for recrystallization inhibition as described in example 3.
  • the plant extract containing only buffer showed an increase in the diameter of the crystals that was at least five times greater than the plant extract sample containing the Protein A-Saf5 fusion protein.
  • the results o this experiment demonstrated recrystallization inhibition when the Protein A-Saf5 fusion protein represented 0.1% of the total protein by mass.
  • the antifreeze gene saf10 (described in example 6A) was cloned into plasmids which were suitable for plant transformation by the method of co-cultivation with Agrobacterium tumefaciens.
  • the vectors were constructed in such a way that the antifreeze gene would be expressed in plants under the control of the 35S promoter which is derived from the cauliflower mosaic virus and which is known to give high levels of expression of foreign genes in plant cells.
  • vectors were the possession of a leader sequence derived from the petunia Cab22L gene, which is known to further enhance expression in plants, and a 3" polyadenylation sequence derived from the Agrobacterium tumefaciens nopaline synthase gene, which is known to permit efficient post-transcriptional processing of messenger RNAs of which it is a part.
  • some of the vectors contained DNA sequences derived from bacterial or plant genes for secreted proteins, in order to produce antifreeze polypeptides which would be secreted from the plant cell.
  • the plasmid p35S(J) :Cab22L-CH contains the CaMV 35S promoter followed by the leader sequence derived from the
  • Cab22L gene of petunia Downstream of these seguences is the bacterial chiA (chitinase A) gene, which has been modified to have a unique Ncol site at the ATG start codon. Beyond the end of the coding sequence for the bacterial chiA gene is a unique BamHI site, followed by the nos (nopaline synthase) polyadenylation signal. Beyond this is a unique Hindlll site. The backbone of this plasmid is the vector pUCll ⁇ , which is commercially available. Thus it is possible to prepare this plasmid in either single or double stranded form. The construction of this plasmid has been published (M.H. Harpster et al. (1988) Mol. Gen.
  • the plasmid pCHIT-503 was derived from the plasmid p35S(J) :Cab22L-CH, by introducing a Smal site by site directed mutagenesis at a position immediately downstream of the codons for the chiA signal sequence.
  • the method of site directed mutagenesis used has been described (T.A. Kunkel, (1985) Proc. Natl. Acad. Sci. USA. 82:488-492).
  • oligonucleotide 5•-TTGCCCGGGGCGGCG-3• which is complementary to the chiA sequence from positions +69 to +83 with a single base pair change at position +75 which creates a Smal site without changing any of the amino acids in the translated protein, was annealed to single stranded p35S(J) :Cab22L-CH which had been prepared from the E . coli strain BW313.
  • the oligonucleotide was extended in the presence of all four deoxyribonucleotide triphosphates and the Klenow fragment of DNA polymerase I and T4 DNA ligase. The polymerase extended and ligated plasmids were transforme into E.
  • the plasmid pCHIT503-21 was derived from the plasmid pCHIT503 by removing a Smal site present in the wild type chiA gene using site-directed mutagenesis. This was done so that the newly introduced Smal site would be the onl Smal site in the plasmid.
  • oligonucleotide 5'-CTTTGCCGCCAGGGAACTCC-3• (which is complementary to the chiA sequence from positions +942 to +961 with a single base pair change at position +951 and which destroys the Smal site but does not change any amino- acids in the ChiA protein) was annealed to single stranded pCHIT503 which had been prepared from the E. coli strain
  • the oligonucleotide was extended in the presence of all four deoxyribonucleotide triphosphates and the Klenow fragment of DNA polymerase I and T4 DNA ligase.
  • the polymerase extended and ligated plasmids were transformed into E. coli HB101. Individual transformants were picked and plasmid DNA from each was screened for the loss of the Smal site. One such transformant was found which had the correct restriction digest pattern, and this was named pCHIT503-21.
  • the plasmid pCHITSOO contains the codons for the tobacco PRlb signal sequence synthesized as two oligonucleotides and cloned as an Ncol-Smal fragment in the plasmid pUCll ⁇ .
  • the oligonucleotides were designed so that when annealed and cloned into pUC118, they would have a Smal site at the 3' end, which if used to clone the PRlb signal sequence fragment into pCHIT503-21 would put the codons for the PRlb signal sequence in the same reading frame as the codons for the ChiA protein.
  • the oligonucleotides were: 5'- CATGGGATTT TTTCTCTTTT CACAAATGCC CTCATTTTTT CTTGTCTCTA CACTTCTCTT ATTCCTAATA ATATCTCACT CTTCTCATGC CCAAAACCC - 3' and 5'- GGGTTTTGGG CATGAGAAGA GTGAGATATT ATTAGGAATA AGAGAAGTGT AGAGACAAGA AAAAATGAGG GCATTTGTGA AAAGAGTAAA AATCCC - 3' .
  • the PRlb protein is a protein whose synthesis is induced by pathogen attack. It is a secreted protein and possesses a signal seguence (J.P. Carr et al. (1987) Mol. Cell Biol.. 7:1580-1583; B.J.C. Cornelissen et al. (1986) EMBO J.. 5:37-40).
  • the plasmid pCHIT-PRSS was derived from the plasmid pCHIT503-21 by replacing the Ncol-Smal fragment from pCHIT503-21 (which carries the codons for the ChiA signal sequence) with the Ncol-Smal fragment pCHITSOO which carries the signal sequence of the PRlb protein from tobacco.
  • pCHIT503-21 DNA was cut with the restriction enzymes Ncol and Smal.
  • pCHITSOO was cut with Ncol and Smal and the smaller fragment released was purified from a polyacrylamide gel.
  • the small fragment was ligated with the Ncol-Smal cut pCHIT503-21 with a large molar excess of the smaller fragment, and transformed into the E. coli strain MV1193.
  • DNA was prepared from some of the transformants, and the desired plasmid was identified by restriction enzyme analysis.
  • the plasmid which carries the PRlb signal sequence fused in frame to the * chiA coding sequence was designated pCHIT-
  • the plasmid pCHIT-PRSS2 was derived from the plasmid pCHITPR-SS by site directed mutagenesis, after it was discovered by DNA sequence analysis that the PRlb signal sequence cloned in the plasmid pCHIT-PRSS carried a single base pair change which would lead to an amino-acid substitution in the PRlb signal sequence. This was a change from T to A at position 12 of the PRlb sequence, which changes a codon for leucine (the wild type sequence) to a codon for phenylalanine.
  • this mutation was corrected back to the wild type, using the same site directed mutagenesis protocol as described above.
  • the oligonucleotide which had been synthesized in order to produce the plasmid pCHITSOO an which coded for the top strand of the PRlb gene was used for the mutagenesis.
  • the correct plasmid was identified by DNA seguence analysis, and was designated pCHIT-PRSS2.
  • the only difference between the two plasmids pCHIT-PRSS and pCHIT- PRSS2 is the single base pair difference in the region of th plasmid coding for the PRlb signal sequence.
  • Fig. 8A The construction of pCHIT503, pCHIT503-21, pCHIT- PRSS and pCHIT-PRSS2 is summarized in Fig. 8A.
  • the plasmid pJJ2964 is a plasmid which has been specifically designed for plant transformation by Agrobacterium tumefaciens. It contains sequences permitting it to replicate both in E. coli and Agrobacterium tumefaciens. and a gene encoding resistance to tetracycline which enables it to be selected for in both these bacteria. It contains the left border and right border sequences of T- DNA which are required for efficient transfer to plant cells and integration into the plant's DNA.
  • the plasmid pAGSlll (P. van den Elzen et al. (1985) Plant Mol. Biol.. 5:149-154) was cut with the restriction enzymes Hindlll and EcoRI, and the overhanging ends were filled in with the Klenow fragment of DNA polymerase I plus the four deoxyribonucleotide triphosphates.
  • the two cleaved DNAs were ligated and transformed into E. coli.
  • a plasmid was identified by restriction enzyme analysis that contained the EcoRI-Hindlll fragment from pAGSlll containing the nptll gene from pAGSlll, and the right and left borders of the T-DNA
  • pJJ1881 pJJ1881 was cut with Clal and BamHI and ligated with pBR322 (a commercially available plasmid) which had been cut with Clal and BamHI, and the ligation product was transformed into E. coli.
  • pJJ2431 A plasmid was identified where the Clal-BamHI fragment from pJJ1881 carrying the nptll gene had been replaced with the small Clal-BamHI fragment from pBR322, which has a Hindlll site downstream of the Clal site. This plasmid was designated pJJ2431.
  • the plasmid pLGVNeo2103 (van den Elzen et al., 1985) was cut with EcoRI, treated with SI nuclease to remove single stranded DNA, and ligated with Clal linkers. The ligation was cut with Clal and the plasmid purified away from the linkers, then religated and transformed into E. coli.
  • a plasmid was identified where the EcoRI site in pLGVNeo2103 had been converted to a Clal site, and this plasmid was designated pAGS109.
  • pAGS109 was cut with Clal and Hindlll, and ligated with pJJ2341 which had been cut wit Clal and Hindlll.
  • a plasmid which contained the nptll gene in the backbone derived from pJJ2341 was identified and designated pJJ2964. The construction of pJJ2964 is shown in Fig. 8B.
  • the DNA was recovered by extracting once with an equal volum of 1:1 phenol and chloroform saturated with TE (10 mM TRIS p 8.0, 1 mM EDTA) , followed by precipitation with 0.3 M NaOAc, 10 ⁇ g of yeast tRNA and 2.5x volumes of ethanol.
  • the purified DNA fragment was resuspended in 20 ⁇ l TE.
  • 2 ⁇ g of pCHIT503-21 was cut with the restriction endonucleases Ncol and BamHI, and electrophoresed on a 0.8% agarose gel.
  • the vector backbone fragment was electroeluted and resuspended i 20 ⁇ l TE.
  • ligase buffer 50 mM NaCl, 100 mM TRIS pH 7.5, 10 mM MgCl 2 , 1 mM dithiothreitol, 1 mM ATP, 1 unit T 4 DNA ligase
  • ligase buffer 50 mM NaCl, 100 mM TRIS pH 7.5, 10 mM MgCl 2 , 1 mM dithiothreitol, 1 mM ATP, 1 unit T 4 DNA ligase
  • coli strain MV1193 and transformants were selected by growth on LB agar containing 75 ⁇ g/ml ampicillin.
  • DNA was prepared from individual colonies and cleaved with the restriction endonucleases Xhol and Hindlll. The predicted size fragments (447 base-pairs) were observed following gel electrophoresis in 0.8% agarose.
  • the correct plasmid was named pCHIT-AFNB.
  • the antifreeze gene was first fused in the correct reading frame to a signal sequence from the bacterial chitinase gene chiA or the tobacco pathogenesis related protein PRlb, as follows. 10 ⁇ g of pGMM5 was digested with the restriction endonucleases Smal and BamHI. The products of the digestion were electrophoresed on a 9% polyacrylamide gel, and a fragment of the expected size (133 base-pairs) was seen. This band was excised from the gel and electroeluted.
  • the DNA was recovered by extracting the buffer once with an equal volume of 1:1 phenol and chloroform saturated with TE, followed by precipitation with 0.3 M NaOAc, 10 ⁇ g of yeast tRNA and 2.5x volumes of ethanol.
  • the purified DNA fragment was resuspended in 20 ⁇ l TE. 2 ⁇ g of pCHIT503-21 was cut with the restriction endonucleases Smal and BamHI, and electrophoresed on a 0.8% agarose gel.
  • This cleavage produced two fragments: the fragment containing the coding region for the mature part of the chitinase protein (i.e., that part of the protein which is left after cleavage of the signal sequence) and the backbone of the vector containing the selectable ampicillin resistance marker, the sequences required for plasmid replication, the CaMV 35S promoter, the Cab22L leader, the codons for the ChiA signal seguence (terminating in a Smal site) , and the nos polyadenylation signal (starting with a BamHI site) .
  • the vector backbone fragment was electroeluted and resuspended in 20 ⁇ l TE.
  • the predicted size fragment (530 base-pairs) was observed following gel electrophoresis in 0.8% agarose. A second cleavage with Ncol was then carried out to confirm that the correct ligation product had been recovered. The predicted fragment of 83 base-pairs was seen following electrophoresis in 8% polyacrylamide. The correct plasmid was named pCHIT- AFSB.
  • a vector was constructed where the antifreeze gene saf10 was fused in frame to the signal sequence from the tobacco PRlb gene, situated downstream from the CaMV 35S promoter with the Cab22L leader, and with the nos polyadenylation signal at the 3' end.
  • the procedure was identical to that described in the previous paragraph, excep that the Smal-BamHI fragment derived from pGMM5 was cloned i to Smal-BamHI cleaved pCHIT-PRSS2.
  • the correct plasmid was identified by restriction analysis of plasmid DNA from the transformants produced from this ligation. Digestion with Xhol and Hindlll released a fragment of size 551 base-pairs, and cleavage with Ncol produced a fragment of 104 base-pairs
  • the desired plasmid was named pCHIT-AFSS2.
  • a vector was constructed where the antifreeze gene saf10 was fused in frame to the mutated signal sequence from the tobacco PRlb gene, and situated downstream from the CaMV 35S promoter with the Cab22L leader, and with the nos polyadenylation signal at the 3' end.
  • the procedure was identical to that described in the previous paragraph, excep that the Smal-BamHI fragment derived from pGMM5 was cloned i to Smal-BamHI cleaved pCHIT-PRSS.
  • the correct plasmid was identified following cleavage of plasmid DNA from the transformants produced from this ligation with Xhol and Hindlll which released a fragment of size 551 base-pairs.
  • the desired plasmid was named pCHIT-AFSS.
  • sequences of the antifreeze genes in the plasmids pCHIT-AFNB, pCHIT-AFSB, pCHIT-AFSS, and pCHIT-AFSS2 are as follows, with the sequence being shown from the initiating ATG to the Hindlll site:
  • Antifreeze gene (saflO) following cloning of NcoI-BamHI into NcoI-BamHI cut pCHIT503. length: 130
  • Antifreeze gene fused in frame to chiA signal sequence. length: 221
  • Antifreeze gene saf10 cloned as pAFSS (with PRlb signal seguence containing the mutation at position 12) length: 242
  • Antifreeze gene saf10 cloned as pAFSS2 length: 242
  • Antifreeze gene (saf10) following cloning of NcoI-BamHI into NcoI-BamHI cut pCHIT503.
  • Antifreeze gene fused in frame to chiA signal sequence.
  • Antifreeze gene saf10 cloned as pAFSS (with PRlb signal sequence containing the mutation at position 12)
  • the entire sequences containing the CaMV 35S promoter, the Cab22L leader, the chiA or PRlb signal sequences if present, the antifreeze gene and the nos polyadenylation signal were transferred into a vector which could be used to transform plant cells.
  • 20 ⁇ g of purified pCHIT-AFNB, pCHlT-AFSB, pCHIT-AFSS or pCHIT-AFSS2 were cut with Bglll and Hindlll.
  • Bglll cuts in the region of DNA 5' to the CaMV 35S promoter
  • Hindlll cuts in the region of DNA 3' to the nos polyadenylation sequence.
  • Hindlll fragments were purified by electroelution from a 0.8 agarose gel, extracted with a 1:1 mixture of phenol and chloroform and precipitated with 0.3 M NaOAc, yeast tRNA and ethanol as described above. The purified fragments were resuspended in 25 ⁇ l TE. Each fragment was then cloned into the binary vector pJJ2964. 10 ⁇ g of pJJ2964 DNA was cut wit the restriction endonucleases BamHI and Hindlll, purified from a 0.8% agarose gel by electroelution, phenol/chloroform extracted, and ethanol precipitated, as described above. Th cut DNA was resuspended in 20 ⁇ l TE.
  • the cleaved plasmid DNA was checked by electrophoresis on a 1% agarose gel for the presence of the correct sized fragment. Fragments of the predicted size were seen in each case, confirming that the correct ligation product had been obtained.
  • the plasmids obtained were named 2964-AFNB, 2964-AFSB, 2964-AFSS and 2964-AFSS2. These were derived from pCHIT-ASNB, pCHIT-AFSB, pCHIT-AFSS and pCHIT- AFSS2, respectively. Details of these constructions are shown in Fig. 8C.
  • A. tumefaciens strain LBA4404 Prior to transformation of plant tissue, the binary plasmids derived from pJJ2964 were introduced into A. tumefaciens strain LBA4404 by triparental mating. Fresh cultures of A. tumefaciens LBA4404 harboring plasmid pAL4404 were grown at 28°C for 24 h from a single colony in minimal A (10.5 g K 2 P0 4 , 4.5 g KH 2 P0 4 , 1 g (NH 4 ) 2 S0 4 , 0.5 g NaCitrate.2H.O) , 1 ml 1 M MgS0 4 .7H 2 0, 10 ml 20% glucose, water to 11) . E.
  • coli HB101 containing the plasmid pRK2013 and E. coli HB101 containing the pJJ2964 derivatives described above were grown for 6 hours in L broth.
  • 0.5 ml of the A. tumefaciens culture was mixed on the same LB agar plate with 0.25 ml of HB101/pRK2013 and 0.25 ml of HB101 containing one of the pJJ2964 derivatives, and the plates were incubated for 24 hours at 28°C.
  • a loopful of bacteria from each plate was then resuspended in 1 ml minimal A and plated at 10°, 10 ⁇ 2 and 10 "4 dilutions on LB plates containing 100 ⁇ g/ml rifampicin and 100 ⁇ g/ml tetracycline. After several days growth at 28"C, individual colonies were restreaked onto minimal A plates containing 1 ⁇ g/ml tetracycline.
  • MS/B5 0.1/1.0 was prepared as follows: A lOx stock of MS major salts was prepared, containing (per liter) 16.5 g NH 4 N0 3 , 19 g KN0 3 , 3.7 g MgSO 4 .7H 2 0, 1.7 g KH 2 P0 4 , 4.4 g CaCl 2 .2H-,0.
  • a 1000X stock of MS minor salts was prepared containing (per liter) 19800 mg MnCl 2 .4H 2 0, 6200 mg H 3 B0 3 , 8625 mg ZnS0 4 .7H 2 0, 830 mg KI, 250 mg NaMo0 4 .2H 2 0; 25 mg CuSO 4 .5H 2 0, 25 mg CoCl 2 .6H 2 0.
  • a 10Ox stock of B5 vitamins was prepared containing per liter 100 mg nicotinic acid, 1000 mg thiamine HCl, 100 mg pyridoxine HCl, 10000 mg myo-inositol.
  • a lOOx stock of MS FeEDTA was prepared containing per liter 3.73 g Na 2 EDTA, 2.78 g FeSO 4 .7H 2 0.
  • MS/B5 0.1/1.0 was made up as follows: Ingredient ' Stock Amount/liter
  • the discs were then placed on solid MS/B5 0.1/1.0 containing 500 ⁇ g/ml cefotaxime and incubated for 3 days at 28°C.
  • the discs were then transferred to selective medium: MS/B5 0.1/1.0 containing 500 ⁇ g/ml cefotaxime and 100 ⁇ g/ml kanamycin.
  • the discs were cultured on this medium under high light fluence with a 16 hour light, 8 hour dark regime at 26°C. After 2-3 weeks, kanamycin resistant callus and subsequently kanamycin resistant shoots begin to appear.
  • rooting medium MS 0.1/1.0 with no naphthalene acetic acid or 6-benzylaminopurine, containing 2 ⁇ M indole butyric acid
  • rooting medium containing 100 ⁇ g/ml kanamycin. Plants that successfully developed roots on this medium were all transformants. They were then transferred to Magenta boxes containing solid MS 0.1/1.0 without naphthalene acetic acid or 6-benzyl aminopyrine.
  • RNA was extracted from leaves of transformed plants and assayed for the presence of the antifreeze mRNA by using the technique of RNase protection.
  • aqueous layer was then transferred to a fresh 30 ml Corex tube containing 0.5 ml 3 M NaOAc pH 6, and 12.5 ml ethanol was added. The contents of the tube were mixed and then chilled to -20°C fo 20 minutes. The tube was then spun at 8,000 rpm for 15 minutes in a Sorvall SS-34 rotor, to pellet the nucleic acid.
  • the pellet was resuspended in 2.5 ml 4 M LiOAc, and incubate at 4°C for 3 hours. The tube was then spun at 8,000 rpm for 15 min. in an SS-34 rotor to pellet the RNA. The pellet was resuspended in 2.5 ml water, to which was added 250 ⁇ l 3 M NaOAc pH 6 and 7 ml ethanol. The tube was spun again at 8,000 rpm for 15 min. and the pellet was washed with 5 ml 70 ethanol. The pellet was dried under vacuum, and then resuspended in 200 ⁇ l water. To establish the presence of the expected mRNA in the RNA extracted from the transformed plants, the technique of RNase protection was used.
  • RNA is digested with enzymes which are specifi for single stranded RNA. If sequences complementary to the probe are present in the RNA preparation, they will anneal with the probe to form a double-stranded RNA which will be resistant to RNase digestion. This can then be detected by gel electrophoresis and autoradiography.
  • BS(-)AF DNA was purified and 5 ⁇ g was digested with EcoRI, which cuts upstream of the ATG of the antifreeze gene. The cut DNA was purified by extraction with phenol and chloroform and precipitated with 0.3 M NaOAc and ethanol. 32 P-labeled RNA complementary to the antifreeze message was synthesized by using the riboprobe reaction as described in the commercial literature from Promega Biotech Inc.
  • the purified labeled probe was resuspended in 25 ⁇ l water. 10 ⁇ g RNA from each one of the six transformed plants, and 10 ⁇ g RNA from a tobacco plant transformed with a different binary vector not containing the antifreeze gene, was dried under vacuum, and then resuspended in 30 ⁇ l hybridization buffer (40 mM PIPES (ph 6.7), 0.4 M NaCl, 1 mM EDTA) . A control tube was also made which contained 10 ⁇ g tRNA from yeast. 1 ⁇ l of probe was added to each sample.
  • the samples were overlaid with 30 ⁇ l mineral oil to prevent evaporation, incubated at 85°C for 5 min., then at 45°C for 18 hours. Digestion with RNase A and Tl RNase and preparation of the samples for loading onto a denaturing 6% polyacrylamide gel was then carried out as described in the commercial protocol from Promega Biotech Inc. Also loaded on the same gel were size markers (pBR322 DNA cleaved with Hpall and labeled with 32 P) and a 500x dilution of the original riboprobe. Following electrophoresis, the gel was fixed for 10 min. in 10% acetic acid, 10% methanol, then dried onto Whatman filter paper No. 1, and autoradiographed, see Fig. 9.
  • the relative intensities of the bands varied, reflecting the known fact that the level of expression of an introduced gene varies between individual regenerated plants from the same transformation experiment.
  • the results of thi experiment showed that a synthetic gene for the antifreeze protein can be introduced into plants, and that this gene is expressed in the plant tissue.
  • the expression of either of these antifreeze constructs would direct the synthesized antifreeze protein to the intercelllular space in transformed plant tissue.
  • the extraction was performed as described above for the 2964-AFN transformants.
  • the presence of mRNA in the RNA extracted from the transformed plants was assayed as described above using the technique of RNase protection and using the same probe as described above. A gel was obtained following electrophoresis, as described above.
  • the relative intensities of the bands varied, reflecting the known fact that the level of expression of any introduced gene varies between individual regenerated plants from the transformation experiment.
  • the results of this experiment showed that a synthetic gene for the antifreeze protein (containing DNA encoding a signal sequence for purposes of yielding, upon translation, antifreeze protein and antifreeze activity in the intercellular space) can be introduced into plants, and that this gene is expressed in the plant tissue.
  • Plasmids 2964-AFNB and 2964-AFSB were introduced into Agrobacterium as described above, and were used to transform tomato.
  • MS/B5 0.1/1.0 was prepare as follows: A lOx stock of MS major salts was prepared, containing (per liter) 16.5 g NH 4 N0 3 , 19 g KN0 3 , 3.7 g MgS0 4 .7H 2 0, 1.7 g KH 2 P0 4 , 4.4 g CaCl 2 .2H 2 0.
  • a lOOOx stock of MS minor salts was prepared containing (per liter) 19800 mg MnCl 2 .4H 2 0, 6200 mg H 3 B0 3 , 8625 mg ZnS ⁇ 4 .7H 2 0, 830 mg KI, 250 mg NaMo0 4 .2H 2 0; 25 mg CuSO 4 .5H 2 0, 25 mg CoCl 2 .6H 2 0.
  • a lOOx stock of B5 vitamins was prepared containing per liter 100 mg nicotinic acid, 1000 mg thiamine HCl, 100 mg pyridoxine HCl, 10000 mg myo-inositol.
  • a lOOx stock of MS FeEDTA was prepared containing per liter 3.73 g Na 2 EDTA, 2.78 g
  • the discs were cultured in this medium under hig light fluence with a 16 hour light, 8 hour dark regime at 26 ⁇ C. After 2-3 weeks, kanamycin resistant callus and subsequently kanamycin resistant shoots began to appear.
  • RNA was extracted from leaves of transformed plants and assayed for the presence of the antifreeze mRNA by using the technique of RNase protection. RNA was extracted from leaves of plants growing in the greenhouse or Magenta boxes. Each transformant was the product of a unique transformation event with the binary plasmid 2964-AFNB (14 plants) or 2964-AFSB (7 plants) . Leaf tissue was taken from each plant, frozen in liquid nitrogen, and ground to fine powder using a mortar and pestle.
  • the powder was transferred to a capped polypropylene tube containing 5 ml phenol (equilibrated with water) , 5 ml chloroform, and 5 ml NTES (0.1 M NaCl, 0.01 M TRIS HCl pH 7.5, 1 mM EDTA, 1% SDS) and the tube was vortexed for 30 seconds.
  • the extraction mix was then transferred to a 30 ml Corex tube and spun at 8,000 rpm for 10 min. in a Sorvall SS- 34 rotor. The upper aqueous layer was removed, and the extraction was repeated until the aqueous layer was clear and there was no precipitation material at the interface between the organic and the aqueous layers.
  • the aqueous layer was then transferred to a fresh 30 ml Corex tube containing 0.5 ml 3 M NaOAc pH 6, and 12.5 ml ethanol was added. The contents of the tube were mixed and then chilled to -20"C for 20 minutes. The tube " was then spun at 8,000 rpm for 15 minutes in a Sorvall SS-34 rotor, to pellet the nucleic acid. The pellet was resuspended in 2.5 ml 4 M LiOAc, and incubate at 4 ⁇ C for 3 hours. The tube was then spun at 8,000 rpm for 15 min. in an SS-34 rotor to pellet the RNA.
  • the pellet was resuspended in 2.5 ml water, to which was added 250 ⁇ l 3 M NaOAc pH 6 and 7 ml ethanol. The tube was spun again at 8,000 rpm for 15 min. and the pellet was washed with 5 ml 70 ethanol. The pellet was dried under vacuum, and then resuspended in 200 ⁇ l water.
  • RNA is digested with enzymes which are specifi for single stranded RNA. If sequences complementary to the probe are present in the RNA preparation, they will anneal with the probe to form a double-stranded RNA which will be resistant to RNase digestion. This can then be detected by gel electrophoresis and autoradiography.
  • BS(-)AF DNA was purified and 5 ⁇ g was digested with EcoRI, which cuts upstream of the ATG of the antifreeze gene. The cut DNA was purified by extraction wit phenol and chloroform and precipitated with 0.3 M NaOAc and ethanol.
  • 32 P-labeled RNA complementary to the antifreeze message was synthesized by using the riboprobe reaction as described in the commercial literature from Promega Biotech Inc. using T3 RNA polymerase. The purified labeled probe wa resuspended in 25 ⁇ l water.
  • the gel was fixed for 1 min. in 10% acetic acid, 10% methanol, then dried onto Whatman filter paper No. 1, and autoradiographed.
  • Plasmid pGMM9 (Example 6) was digested with restriction endonuclease Hindlll, the staggered ends were made blunt by filling-in with the Klenow fragment of DNA polymerase and dNTP's, and the resulting blunt ends were religated.
  • the goal of this manipulation was to delete a portion of the sequences encoding Protein A in pGMM9 and to place the downstream and upstream sequences in the same reading frame.
  • the desired plasmid was isolated by transformation into E. coli and as expected, it had acquired a recognition site for Nhel at the point of deletion.
  • the new plasmid, pLVC107 encoded a fusion protein related to Protein A, but smaller, and lacking any methionine residues except at its N-terminus and at the point of fusion to saflO (where fusions to other antifreeze genes would subsequently also be made, as described below) .
  • This fusion protein is referred to as mini-Protein A-saflO.
  • the "mini-Protein A" portion retains a single functional IgG binding site permitting purification by affinity chromatography and visualization after Western blotting.
  • a Hindlll site was introduc into pLVC107 by substitution of the 0.95 kb Pst/Aatll fragment from pUC118 into the corresponding sites of pLVC107 generating the new vector, pLVClO ⁇ .
  • pLVClOS retains only a upstream segment of saf10, still fused in the correct readi frame to the mini-Protein A gene.
  • mini-Protein A was constructed by substituting the small NcoI/BamHI fragment from pGMM3 (Example 5) into the corresponding sites of pLVC107, to yield plasmid pLVCHO.
  • the fusions of mini-Protein A to saf4 and saf5 were constructed by substituting the small Nhel/Hindlll fragments from pLVC85 and pLVC86 (Example 2) into the corresponding sites of pLVC108, to yield plasmids pGMM14 and pGMM15 respectively.
  • the upstream portions of the original saf4 and saf5 genes are replaced by the upstream portion of saf10 present in pLVClO ⁇ .
  • the only difference in structure is that in pGMM14 and pGMM15, saf4 and saf5 begin with the sequence MDTASD (in contrast to MAADTASD previously) .
  • saf4b and saf5b These versions of saf4 and saf5 will be referred to as saf4b and saf5b, respectively.
  • the fusion of mini-Protein A to saf6 was obtained by substituting the small Ncol/Hindlll fragment from pGJ15l (Example 4) into the corresponding sites of pLVClO ⁇ , to yiel plasmid pGMM13.
  • the series of plasmids encoding the mini-Protein A saf fusions was transformed into E. coli K12 strain JC10291 containing plasmid pRITcI857 (B. Nilsson and L. Abrahmsen,
  • the pRITcI857 plasmid encodes a temperature-sensitive repressor of the lambda promoter in the fusion plasmids, allowing the strains to be cultured at 28°C prior to induction of fusion protein synthesis at 42°C.
  • the strains were cultured individually in 500 ml L each at 28°C until reaching O.D. (600) of 1. At this point the temperature was raised to 42°C by addition of equal volumes of LB at 56°C, and incubation was continued at 42°C for a further 90 minutes. After harvesting, the fusion proteins were then extracted and purified as described for Protein A-saflO (Example 7) .
  • mini-Protein A-saf6 ++ - NT NT mini-Protein A-saf ⁇ ++ + NT NT mini-Protein A-saf10 ++ - - NT mini-Protein A-saf4b ++ ++ - mini-Protein A-saf5b ++ ++ +
  • Example 9 Induction of the mini-Protein A-saf fusion protein was carried out as described in Example 9 above. Cells were lysed and fusion proteins purified as in Example 6. The release of the naked antifreeze peptides by cyanogen bromide was carried out as in Example 6. The cleavage mixtures were filtered and concentrated by means of lOkDa. and 3kDa. cutof filters, as described in Example 6. The concentrates were analyzed by HPLC chromatography over a C-l ⁇ column, with elution by a linear gradient from 65% solution A/15% solutio B(A: 1% trifluoroacetic acid in water; B: acetonitrile) to 10% solution A/90% solution B.
  • the naked Saf peptides were visualized as single peaks eluting at 72% A/2 ⁇ % B (SaflO) or at 62%A/3 ⁇ % B (Saf ⁇ and Saf ⁇ ) . This analysis showed each naked Saf peptide to be greater than 75% pure in the 3kDa. filter retentate.
  • concentrations of the purified naked peptides were estimated by the BCA protein assay and then adjusted to 100 ug/ml (100 parts per million) .
  • EXAMPLE 11 Cryopreservation of yeast by intracellular expression of a Protein A-Saf5 fusion protein.
  • Plasmid pRLM105 was treated with the restriction enzyme Hindlll under conditions that produced a single DNA fragment containing the Protein A-Saf5 coding sequences. The sticky ends of this fragment were filled in by enzymatic addition o dNTPs as described in Maniatis and ligated to BamHI linkers (Pharmacia) . This fragment was then ligated into the BamHI site of pUCll ⁇ to yield plasmid pRLM1054B. Plasmid pRLM1054 was treated with restriction enzymes (Bell and BamHI) to release an approximately 1.0 kbp fragment containing the
  • Protein A-Saf5 coding seguences which was inserted into the yeast expression vector YEpRMl.
  • the plasmid YEpRMl was constructed by inserting a synthetic double stranded oligonucleotide into the unique EcoRI site downstream from the yeast 3-phosphoglycerate kinase promoter fragment in the plasmid YEplPT (Mol. & Cell Biol. (19 ⁇ 6) 6:l ⁇ l2-1819 and Science (1983) 219:620-625).
  • the double stranded oligonucleotide consisted of two chemically synthesized oligonucleotides with the sequences 5' AATTCCATGGATCCCGGGCGGCCGC 3', and
  • AATTGCGGCCGCCCGGGATCCATGG 3' which were annealed togethe resulting in a 21 bp double stranded segment with EcoRI compatible sticky ends.
  • the oligonucleotide wa also designed such that only one of the ends can be cut with EcoRI following ligation into the EcoRI site of YEplPT.
  • the BclI-BamHI fragment containing the Protein A-Saf5 sequences from pRLM1054B was ligated into the BamHI site of YEpRMl to yield YEpRM3.
  • Plasmid YEpRM3 was transformed into the yeast strain 20B-12 with the genotype trpl. pep4-3 (Mol. & Cell
  • Transformed yeast cells were grown under selectiv conditions in SD medium to a concentration of approximately X 10 7 cells per ml, harvested by centrifugation, and washed with 1/50 volume water.
  • the cell pellet was resuspended in volumes 3X Laemmli Buffer (Nature (1970) 227:680-665) and disrupted by agitation for 1 minute in a mini-beadbeater (BioSpec Products) in the presence of 2/3 volume glass beads (0.5 mm diameter).
  • the disrupted cells were placed into a boiling water bath for 5 minutes, followed by centrifugation for 1 minute in a microcentrifuge.
  • the supernatant was run on SDS polyacrylamide gels, transblotted to nitrocellulose filters, and examined by western blot analysis using antibodies directed against the Protein A domain of the fusion protein.
  • the results of this analysis showed the presence of a unique protein band of the correct size in extracts from yeast cells containing the Protein A-Saf5 gene when compared to extracts from cells lacking the Protein A- Saf5 gene. This demonstrates that the transformed yeast are expressing the Protein A-Saf5 fusion protein.
  • FIG. 10 shows the developmen of recrystallization over a period of one hour in extracts from yeast cells expressing the Protein A-Saf5 gene compared to extracts from cells lacking the Protein A-Saf5 gene.
  • Slide 10-1 is a photograph of the two splats shortly after freezing and transfer (within 5 minutes)
  • slide 10-2 shows the same two splats after approximately 15 minutes
  • slide 10-3 shows the same splats after approximately 30 minutes
  • slide 10-4 shows the splats after a period of one hour.
  • the splat on the right is from yeast cells expressing the Protein A-Saf5 gene and the splat on the left is from yeast cells lacking the Protein A-Saf5 gene.
  • Yeast cells were grown in liquid culture under selective conditions, subjected to various rates of freezin thawing and challenged for their ability to grow on agar plates.
  • yeast cells lacking the Protein A-Sa gene were treated in-parallel.
  • the yeast cells were grown late log or early stationary phase in SD medium, concentrat by centrifugation to a volume of 0.02 ml, and cooled by immersion in a dry ice-ethanol bath to -70°C (a rate of 95 ⁇ C/min.). The cells were then transferred to a liquid nitrogen bath and cooled rapidly to -196"C to ensure intracellular ice formation.
  • Thawing was performed by transfer to water baths maintained at temperatures ranging from 0 ⁇ C to 37 ⁇ C (corresponding to thawing rates from 26 to 64°C/min.). Following thawing, the cells were diluted, plated on YPD agar, allowed to grow at 30 " C, and counted. The number of cells that survive freezing-thawing was calculated as a percent of the number of cells grown under identical conditions but not frozen. The increase in viability as a consequence of intracellular expression of t Protein A-Saf5 gene was calculated as the number of survivi cells containing the Protein A-Saf5 gene compared to the number of surviving cells lacking the Protein A-Saf5 gene.
  • Plasmid pRLM1054B (described in Example 11) was transformed into a recombination proficient bacterial host, E.coli Gmll9 (Marinus, M.G. , 1989, Ann. Rev. Genet., 2L, 113 132) , to produce .in vivo deletions of the 33 bp tandem repeats present within the Saf5 nucleotide coding sequences. A deletion of one of the repeats within Saf5 will produce Saf4 (shown in Fig. 6F) . A BclI-BamHI fragment containing the Protein A-Saf4 sequences was ligated into the BamHI sit of YEpRMl (described in Example 11) to yield YEpRM4. Restriction enzyme analysis of plasmid YEpRM4 confirmed the presence of the Saf4 nucleotide sequences.
  • Plasmid YEpRM4 was transformed into the yeast strain 20B-12 and examined by Western blot analysis as described in Example 11. The results of this analysis showe that cell extracts from YEpRM4 produced a unique protein ban of the correct size when compared to cell extracts of YEpRM3 This demonstrates that the transformed yeast are expressing the Protein A-Saf4 fusion protein.
  • the recrystallization inhibition activity of the Protein A-Saf4 fusion protein expressed in YEpRM4 was determined by the splat assay as described in Example 3. Crude cell lysates were prepared from transformed yeast containing YEpRM4 as described in Example 11. Fig. 11 shows the development of recrystallization over a period of one hour in extracts from yeast cells expressing the Protein A- Saf4 gene compared to extracts from cells lacking the Protei A-Saf4 gene.
  • Slide 11-1 is a photograph of the two splats shortly after freezing and thawing (within 5 minutes) , while slide 11-2 shows the same two splats after approximately 15 minutes, slide 11-3 shows the same splats after approximatel 30 minutes, and slide 11-4 shows the splats after a period o one hour.
  • the splat on the right is from yeast cells expressing the protein A-Saf4 gene and the splat on the left is from yeast cells lacking the Protein A-Saf4 gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogen, Water And Hydrids (AREA)

Abstract

De nouveaux procédés permettent d'améliorer au moyen de polypeptides anti-congélateurs la résistance de matériaux organiques à la congélation. Ces polypeptides augmentent la durée de conservation de produits alimentaires et biologiques et protègent des produits végétaux, par exemple pendant leur croissance. On peut produire ces polypeptides anti-congélateurs, ou leurs protéines de fusion, par des techniques chimiques ou de recombinaison d'ADN, puis les purifier à des fins diverses.
EP19900909325 1989-05-10 1990-05-10 Antifreeze polypeptides Withdrawn EP0472662A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US350481 1989-05-10
US07/350,481 US5118792A (en) 1989-05-10 1989-05-10 Ice crystal growth suppression polypeptides and method of making
US50771690A 1990-04-10 1990-04-10
US507716 1990-04-10

Publications (2)

Publication Number Publication Date
EP0472662A1 true EP0472662A1 (fr) 1992-03-04
EP0472662A4 EP0472662A4 (en) 1992-10-07

Family

ID=26996633

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900909325 Withdrawn EP0472662A4 (en) 1989-05-10 1990-05-10 Antifreeze polypeptides

Country Status (5)

Country Link
EP (1) EP0472662A4 (fr)
JP (1) JPH04505329A (fr)
AU (1) AU648028B2 (fr)
CA (1) CA2056434A1 (fr)
WO (1) WO1990013571A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089521B2 (ja) * 1990-01-17 1996-01-31 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 極洋の魚類から単離および精製された熱ヒステリシスタンパク質
CA2110510C (fr) * 1991-06-13 1999-08-24 Marilyn Griffith Amelioration de la tolerance des plantes au froid
US5852172A (en) * 1991-06-13 1998-12-22 University Of Waterloo Cold tolerances in plants
DE69333718T2 (de) * 1992-01-14 2005-12-01 Ajinomoto Co., Inc. Gen, das für eine Fisch-Transglutaminase kodiert
WO1994003617A1 (fr) * 1992-07-29 1994-02-17 Unilever N.V. Procede de production de peptides antigel
US5837545A (en) * 1993-01-21 1998-11-17 Research Corporation Technologies, Inc. Genes, polypeptides, and compositions for cold tolerance in plants
US5676985A (en) * 1994-10-12 1997-10-14 Hsc Research And Development Limited Partnership Antifreeze polypeptide-expressing microorganisms useful in fermentation and freezing of foods
AU697926B2 (en) * 1995-01-05 1998-10-22 Regents Of The University Of California, The Prevention of leakage during thermotropic phase transition in liposomes and biological cells
KR19990082185A (ko) * 1996-01-31 1999-11-25 안네 마리 크리스챤 세포내 부동화 폴리펩티드 및 핵산
EP0843010A1 (fr) 1996-11-19 1998-05-20 Unilever Plc Polypeptides antigel de carotte
TR199900145T2 (xx) * 1996-07-26 1999-03-22 Unilever N.V. Is�ya kararl� antifriz proteini ihtiva eden dondurulmu� g�da �r�n�.
GB2315661B (en) 1996-07-26 2000-05-03 Unilever Plc Frozen food product
EP0966206B1 (fr) 1997-03-14 2005-05-25 Unilever N.V. Produit alimentaire congele contenant des peptides antigel
GB9801408D0 (en) * 1998-01-22 1998-03-18 Unilever Plc Frozen food product
GB9801410D0 (en) 1998-01-22 1998-03-18 Unilever Plc Frozen food product
US6429293B1 (en) 1998-06-26 2002-08-06 Hsc Research And Development Limited Partnership Sculpin-type antifreeze polypeptides and nucleic acids
NZ547506A (en) 2003-11-24 2010-01-29 Agriculture Victoria Serv Pty Ice recrystallisation inhibition protein or antifreeze proteins from deschampsia, lolium and festuca species of grass
CN101267747B (zh) 2005-09-23 2012-11-28 荷兰联合利华有限公司 乳油化减少的充气产品
DE602006004369D1 (de) 2005-09-23 2009-01-29 Unilever Nv Durchlüftete produkte mit niedrigem ph-wert
ES2306039T3 (es) 2005-12-21 2008-11-01 Unilever N.V. Dulce aireado congelado.
US20090136649A1 (en) 2006-03-13 2009-05-28 Nippon Suisan Kaisha Ltd. Protein having ice nucleation activity
EP1917865B1 (fr) 2006-10-20 2012-03-28 Nestec S.A. Peptides d'origine laitière structurant la glace
PL2201084T3 (pl) 2007-10-04 2013-11-29 Petr Dejmek Sposób konserwacji materiału roślinnego
JP2010004875A (ja) * 2008-05-28 2010-01-14 Kaneka Corp 油脂組成物及びその製造方法
BRPI0919788A2 (pt) 2008-10-16 2016-09-06 Unilever Nv solução aquosa de hidrofobina contendo antiespumante
ES2706742T3 (es) 2013-12-02 2019-04-01 Dsm Ip Assets Bv Proteína estructuradora del hielo
EP3293240B1 (fr) * 2015-05-07 2020-04-08 The School Corporation Kansai University Agent ayant une activité d'anti-nucléation de la glace
WO2016193292A1 (fr) 2015-06-02 2016-12-08 Dsm Ip Assets B.V. Utilisation de la protéine structurante de la glace afp19 exprimée dans des souches fongiques filamenteuses pour la préparation de produits alimentaires
KR101678392B1 (ko) 2016-09-30 2016-11-22 (주)넥스젠바이오텍 항산화 기능 및 피부 세포 증식 효과가 증가된 부동화 단백질 및 인간 상피세포성장인자를 포함하는 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PROTEIN ENGENEERING vol. 3, no. 2, November 1989, IRL PRESS OXFORD, ENGL. pages 145 - 151; I.D. PETERS ET AL.: 'Biosynthesis of winter flounder antifreeze proprotein in E. coli' *
See also references of WO9013571A1 *

Also Published As

Publication number Publication date
AU648028B2 (en) 1994-04-14
CA2056434A1 (fr) 1990-11-11
WO1990013571A1 (fr) 1990-11-15
EP0472662A4 (en) 1992-10-07
AU5814390A (en) 1990-11-29
JPH04505329A (ja) 1992-09-17

Similar Documents

Publication Publication Date Title
AU648028B2 (en) Antifreeze polypeptides
US5118792A (en) Ice crystal growth suppression polypeptides and method of making
US5597945A (en) Plants genetically enhanced for disease resistance
CA1321157C (fr) Plantes genetiquement ameliorees, a plus grande resistance aux maladies
EP0455665B1 (fr) Production de semences hybrides
US6015940A (en) Virus resistant potato plants
Kenward et al. Type II fish antifreeze protein accumulation in transgenic tobacco does not confer frost resistance
US5866778A (en) Newly characterized oxalate and uses therefor
EP0567648A1 (fr) Plantes resistant au froid et leur production.
EP0941332B1 (fr) Polypeptides antigel tires de la carotte
US6852841B1 (en) Frozen food product
US6653533B1 (en) Nucleic acids encoding proteins with pathogen resistance activity and plants transformed therewith
US7081568B2 (en) Transgenic plants expressing temporin peptides
JP2002530274A (ja) プロテアーゼ分解に対する安定性の高いペプチド
US6960705B2 (en) Nucleic acid encoding a hypersensitive response elicitor from Xanthomonas campestris
JPH11504202A (ja) 植物における花の誘導の制御およびその使用法
CA2110403A1 (fr) Proteines biocides
AU618011B2 (en) Preparation of novel protein sweeteners-monellin type
US5478923A (en) Class of low calorie protein sweeteners
WO1988010303A1 (fr) Preparation de nouveaux edulcorants proteiniques
JP5892492B2 (ja) 凍結耐性が付与された植物体の生産方法およびその利用
JP2000245463A (ja) プロモーター

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920817

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950509

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971202